Previous close | 0.8000 |
Open | 1.2000 |
Bid | 0.8000 |
Ask | 4.5000 |
Strike | 10.00 |
Expiry date | 2024-05-17 |
Day's range | 0.7500 - 1.2000 |
Contract range | N/A |
Volume | |
Open interest | 164 |
Q1 2024 Arcutis Biotherapeutics Inc Earnings Call
Explore key financial outcomes, product launches, and strategic initiatives as Arcutis Biotherapeutics navigates through a dynamic market landscape.
First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '23 and 59% vs. Q4 '23Continued gross-to-net (GTN) improvement with blended GTN across products now in the low 60 percent rangeSustained growth in demand for cream and remarkable uptake of foam launched in JanuaryJuly 7, 2024 Prescription Drug User Fee Act (PDUFA) action date for roflumilast cream, 0.